Krystal Biotech sets 2026 R&D and SG&A expense guidance at $155M-$165M
Krystal Biotech updated its 2026 non-GAAP R&D and SG&A expense guidance to $155 million-$165 million.
Related stories
Site Centers Q3 FFO per Share: USD -0.06
L impact | EARNINGS | Nov 02, 2026, 09:20 PM UTC
Nasdaq 100 Enters Correction as Chipmaker Selloff Offsets Oil Slump — US Market Wrap
US stocks came under pressure as another selloff in semiconductor shares overshadowed a sharp decline in oil prices, with hopes for diplomatic progress toward ending the war in Ira
H impact | EARNINGS | Nov 02, 2026, 09:20 PM UTC
Tennant reports Q3 EPS of USD 1.12
L impact | EARNINGS | Nov 02, 2026, 09:19 PM UTC
Metallus Q3 Sales Rise 10% on Customer Demand
M impact | EARNINGS | Nov 02, 2026, 09:19 PM UTC
Upwork Sees 4Q Adjusted EPS of 30c–32c
M impact | EARNINGS | Nov 02, 2026, 09:18 PM UTC
People Incorporated forecasts FY2026 operating income of $6M-$49M
M impact | EARNINGS | Nov 02, 2026, 09:18 PM UTC